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The polycation liposome (PCL), a recently developed gene transfer system, is simply prepared by a modification of liposomes with
cetylated polyethylenimine (PEI), and shows remarkable transgene efficiency with low cytotoxicity. In the present study, we investigated the
applicability of PCLs for in vivo gene transfer, since the PCL-mediated transgene efficiency was found to be maintained in the presence of
serum. PCLs composed of dioleoylphosphatidylethanolamine (DOPE) with 5 mol% cetyl PEI (PEI average mr. wt. 1800), were superior for
transfection to those of dipalmitoylphosphatidylcholine (DPPC) and cholesterol (2:1 as molar ratio) with 5 mol% cetyl PEI in vitro, although
the latter PCLs were more efficient for gene transfer in vivo. PCL–DNA complexes were injected into mice via a tail or the portal vein, with
the DNA being a plasmid encoding green fluorescent protein (GFP) or luciferase; and the expression was monitored qualitatively or
quantitatively, respectively. Tail vein injection resulted in high expression of both GFP and luciferase genes in lung, and portal vein injection
resulted in high expression of both genes in the liver. Concerning the gene delivery efficiency, the PCL was found to be superior to PEI or
cetyl PEI alone. The optimal conditions for in vivo transfection with PCLs were also examined.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Gene transfer; Transfection; Liposome; Polycation; Polyethylenimine1. Introduction
Gene delivery is interesting issue in bioscience and
medicine [1,2]. For in vivo gene delivery, efficient and safe
gene transfer systems are awaited [3]. The present trans-
fection systems can be basically classified into two catego-
ries, namely, viral systems and nonviral systems. Nonviral
systems are quite safe and easier for mass production than
viral systems [4,5], although the efficiency for gene transfer
with the former is far less than that obtained with the latter
[6]. Therefore, many attempts have been made to develop0005-2736/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0005-2736(03)00109-3
Abbreviations: DOPE, dioleoylphosphatidylethanolamine; DPPC, di-
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E-mail address: oku@u-shizuoka-ken.ac.jp (N. Oku).more efficient nonviral systems. Among them, cationic
liposomes [7,8] and polycations [9,10] are widely used.
Both cationic liposomes and polycations form a complex
with anionic DNA molecules and are thought to deliver the
gene through the endosomal pathway [11]. Destabilization
of the endosomal membrane by cationic liposomes may
trigger efficient cytosolic delivery of DNA since the incor-
poration of phosphatidylethanolamine, a nonbilayer phos-
pholipid that forms hexagonal II phase at low pH, as a
component of cationic liposomes is known to increase the
transfection efficiency [12–14]. The key step of gene
delivery mediated by cationic liposomes, however, is
thought to be the entry of cytosolic DNA into the nucleus
[15,16]. Therefore, gene delivery is cell cycle-dependent to
some extent, and transfection is effectively achieved in
dividing cells. On the other hand, polycations, which may
deliver DNA to the cytoplasm from the endosome due to the
so-called ‘‘proton-sponge effect’’ [17–19], enter the nucleus
as a complex form with DNA from the cytosol [20,21]. In
fact, polyethylenimine (PEI) with MW of 25,000, one of the
commonly used polycations, has the ability to enter theed.
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DNA entry from the cytoplasm is accelerated by polyca-
tions.
We previously developed the polycation liposome (PCL)
as a novel nonviral gene transfer system, which may possess
the advantageous properties of both cationic liposomes and
polycations for gene delivery [23,24]. PCLs can be simply
prepared by the modification of the liposomal surface with
cetylated PEI with a molecular weight of 600 to 1800. PCLs
showed various advantages such as high efficiency of gene
transfer, low cytotoxicity, without the requirement of a
nonbilayer lipid as a liposomal component, and enhanced
efficacy of gene transfer in the presence of serum. In the
present study, we applied PCLs to in vivo transfection, and
observed that such liposomes were actually effective for in
vivo transfection.2. Materials and methods
2.1. Materials
Synthesis of cetyl PEI was performed as described
previously [23]. In brief, PEI with an average molecular
weight of 1800 (Dow Chemical, Midland, MI, USA) was
purified by ultrafiltration, and refluxed with an appropriate
amount of cetyl bromide in the presence of triethylamine in
chloroform solution. After purification of the cetyl PEI, the
products were identified by NMR. Integration of the proton
NMR spectrum of the product in D2O indicated that 24
mol% of cetyl groups per residue mole of ethylenimine unit
was grafted into the polymer. The stoichiometric formula of
the polymer was (C2H4N)43(C16H33)10.
Dipalmitoylphosphatidylcholine (DPPC) and dioleoyl-
phosphatidylethanolamine (DOPE) were kindly donated
by Nippon Fine Chemical Co. Ltd., Hyogo, Japan. Choles-
terol was purchased from Sigma.
2.2. Preparation of PCL and PCL–DNA complex
PCLs were prepared as follows: Cetyl PEI, DPPC, and
cholesterol (5:67:33 as a molar ratio) were dissolved in
chloroform, dried under reduced pressure, and stored in
vacuo for at least 1 h. The liposomes were produced by
hydration of the thin lipid film with sterilized distilled water
(1 mM as final concentration of lipids). This liposomal
solution was frozen and thawed three times by using liquid
nitrogen, and sonicated for 10 min with a bath-type soni-
cator. PCLs were also prepared with cetyl PEI and DOPE
(5:100) or cetyl PEI, DPPC, and cholesterol (5:100:100) in
some experiments.
A plasmid encoding the green fluorescent protein (GFP)
gene, pEGFP-C1 (Clonetech Laboratories Palo Alto, CA.
USA), or that encoding the luciferase gene, pCAG-luc3 (a
gift of DNAVEC Institute, Tsukuba, Ibaraki, Japan), was
amplified in E. coli JM109 (Nippon Gene, Toyama, Japan)and purified by QIAfilterk Plasmid Mega Kit (Qiagen).
The purity of the plasmids was confirmed by agarose gel
electrophoresis. Quantification of plasmid DNA was per-
formed by use of bisbenziamide H33258 (Hoechst 33258,
Wako) where the standard curve was obtained at 356-nm
excitation and 458-nm emission wavelengths, respectively,
by using EDNA/HindIII digest (BioLabs) as a control. One
microgram of plasmid DNA, which contained about 3 nmol
DNA phosphorus, was dissolved in Tris–EDTA buffer, pH
8.0, and was mixed with 51.4-Al PCL solution (1 mM as
lipids) at optimal nitrogen in PEI and DNA phosphorus (N/
P) ratio (36 eq.). After the addition of RPMI1640, the
mixture was incubated for 20 min at room temperature
before use. Other N/P ratios were also used in some experi-
ments. Since PEI molecule consists of about 25% primary,
50% secondary, and 25% tertiary amines before grafting
cetyl groups, not all of PEI nitrogens have positive charges
at physiological pH. The complex formation between PCL
and DNA was analyzed by agarose gel electrophoresis, and
unbound DNAwas observed up to an N/P ratio of 9 eq. but
not at 12 eq. or more, suggesting that the charge of the
complex is neutralized between 9 and 12 eq. and is positive
at and above 12 eq. (data not shown).
The size and f-potential of the PCLs mainly used in this
study, namely, PCL composed of cetyl PEI, DPPC, and
cholesterol (5:67:33 as a molar ratio) were 184F30 nm and
22.1 mV, respectively; and those after complexation with 36
eq. DNA were 488.2F12.4 nm and 21.9F0.4 mV, respec-
tively. The data indicated that the complex of PCL and DNA
at 36 eq. N/P ratio was still positively charged. The f-
potential of PCLs was determined in 1 mM phosphate
buffer, pH 7.4, at 25 jC by use of an ESL-800 apparatus
(Otsuka Denshi, Osaka, Japan).
Structures of Cetyl PEI, PCL, and PCL/DNA complex
are schematically shown in Fig. 1.
2.3. Gene transfer in vitro
COS-1 cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS, JRH Biosciences, Lenexa, KS, USA) under a
humidified atmosphere of 5% CO2 in air. One day before
gene transfer, 1105 COS-1 cells were seeded onto each of
several 35-mm dishes (Corning) and incubated overnight in
a CO2 incubator. Then, the cells were washed twice with
DMEM, and PCL–DNA complexes (0.25 ml, 1 Ag DNA)
were added to them. After incubation for 3 h at 37 jC in the
presence or absence of 50% FBS, the cells were washed
twice with DME medium and cultured for another 48 h in 2
ml of DME medium supplemented with 10% FBS. Expres-
sion of the GFP-gene in COS-1 cells was observed under a
fluorescence microscope (Olympus, IMT-2). Quantitative
assay was done as follows: The cells in 35-mm dishes were
washed with phosphate-buffered saline (PBS), solubilized
with 1% reduced Triton X-100 (Aldrich Chemical Co. Inc.)
for 30 min, transferred into tubes, and centrifuged at 3000
Fig. 1. Scheme of cetylPEI, PCL, and PCL–DNA complex.
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was measured with an excitation wavelength of 493 nm and
an emission one of 510 nm by use of a fluorescence
spectrophotometer (Hitachi, F-4010).
2.4. Turbidity assay
PCLs composed of cetyl PEI and DOPE (5:100) or cetyl
PEI, DPPC, and cholesterol (5:67:33) were complexed with
pEGFP-C1 plasmid at an N/P ratio of 24 eq. and mixed with
50% FBS. After a 60-min incubation at 37 jC, the turbidity
of the solution was determined at 600 nm with a spectro-
photometer (Beckman, DU-17) with a reference cell of 50%
FBS solution.
2.5. Gene transfer in vivo
PCL (1.03 or 1.54 Amol as lipids) complexed with
pCAG-luc3 or pEGFP-C1 plasmid (20 or 30 Ag plasmid
DNA, respectively) was injected into a tail or the portal vein
of 8-week-old ddY male mice (Japan SLC Inc., Shizuoka,
Japan), which had been anesthetized with sodium pentobar-
bital (0.05 mg/g body weight). For the injection of PCL–
DNA complexes into the hepatic portal system, an incision
was made along the midline of the abdomen to expose the
large vein located in the mesentery. Mice were anesthetizedwith diethyl ether at 24 h after injection, and perfused with
saline. Then, the heart, lungs, liver, spleen, and kidneys
were removed for analysis.
For a quantitative assay, each organ was homogenized in
a lysis buffer (0.05% Triton X-100, 2 mM EDTA, 1 mM
phenylmethane sulfonyl fluoride, and 0.1 M Tris HCl, pH
7.8), frozen and thawed twice, and centrifuged (20,000g,
10 min). Luciferase activity was assayed with a Pikkagene
Assay Kit (Toyo Ink Co., Ltd.) by using a luminescence
photometer (ATTO, AB-2200), and expressed in relative
luciferase units (RLU). The protein concentration of cell
lysates was determined by using a BCA Protein Assay Kit
(Pierce). Then, the gene expression was expressed as
luciferase amount (pg)/mg protein where 1 pg luciferase
was equal to 1.476105 RLU (r2=0.997). For a qualitative
assay, each organ was placed on glass slides and examined
under a fluorescence microscope equipped with a CCD
camera.
The animals were cared for according to the animal
facility guidelines of the University of Shizuoka.
2.6. Statistical analysis
Variance in a group was evaluated by the F test, and
differences in mean tumor volume were evaluated by Stu-
dent’s t test. A significant difference was obtained at P<0.05.
Fig. 3. Turbidity change of PCL–DNA complex in the presence of serum.
PCLs composed of cetyl PEI and DOPE at a molar ratio of 5:100 (A) or
cetyl PEI, DPPC, and cholesterol at one of 5:67:33 (B) were complexed
with 1 Ag of plasmid DNA, pEGFP-C1, at a 24 eq. N/P ratio. PCL–DNA
complexes were incubated in the presence (solid bars) or absence (open
bars) of 50% FBS for 1 h; and the turbidity, an indicator of complex
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3.1. Gene transfer mediated by PCLs in vitro and the effect
of serum on their stability
At first, the efficiency of transgene expression following
delivery by PCL composed of DOPE or DPPC/cholesterol
(2:1) in vitro was examined in the presence or absence of
50% FBS. The expression of the GFP gene is shown in
Fig. 2. As is apparent from the figure, PCLs composed of
DOPE were more efficient for transgene expression than
those of DPPC/cholesterol. Furthermore, the efficacy was
about twice enhanced in the presence of serum in the case
of PCL composed of DOPE, whereas the serum-enhancing
effect was minimal for PCL composed of DPPC/choles-
terol. The PCL and plasmid DNA ratio did not so much
influence the expression at N/P ratios between 12 and 48
eq. This study thus suggested that PCLs composed of
DOPE were suitable as vector in vitro.Fig. 2. PCL-mediated gene transfer in vitro. PCLs composed of cetyl PEI
and DOPE at a molar ratio of 5:100 (A) or of cetyl PEI, DPPC, and
cholesterol at one of 5:67:33 (B) were complexed with 1 Ag of plasmid
DNA, pEGFP-C1, at various N/P ratios. COS-1 cells were incubated with
PCL–DNA complexes for 3 h at 37 jC in the presence (solid bars) or
absence (open bars) of 50% FBS. At 48 h after transfection, the cells were
solubilized and the fluorescence intensity was then determined. Data
represent the meanFS.D. (n=3). Asterisks indicate a significant difference
from the data in the absence of serum (P<0.01).
aggregation, was recorded at 600 nm. Data represent the meanFS.D.
(n=3). Asterisk indicates a significant difference from the data in the
absence of serum (P<0.01).In vivo usage, however, is sometimes quite different.
Thus we examined the stability of PCL–DNA complexes in
the presence of serum by monitoring the turbidity change.
As shown in Fig. 3, the turbidity of PCLs composed of
DPPC and cholesterol with cetyl PEI did not change in the
presence of serum, although that of PCLs composed of
DOPE increased in the presence of serum. Therefore, even
though PCLs composed of DOPE is suitable for in vitro use,
it is possible that PCL composed of DPPC/cholesterol
would be more suitable for in vivo use than those of DOPE.
Actually, that was the case, as shown below. Before that, we
determined the PCL-mediated gene transfer in vivo.
3.2. Gene transfer mediated by PCLs in vivo
Transgene expression with gene delivery by PCLs was
examined in vivo by using two routes of administration; tail
and portal vein. Plasmids (20 Ag per mouse) encoding the
luciferase or GFP gene were used as reporter genes for
quantitative or qualitative assay, respectively. As shown in
Fig. 4A and B, GFP fluorescence was observed in the lungs
or liver, when PCL–pEGFP-Cl plasmid complexes were
injected into mice via a tail or the portal vein, respectively.
Interestingly, the fluorescence was observed only in certain
parts of the organs, but almost all cells in a fluorescent
region were fluorescent. Other organs examined, namely,
heart, liver, spleen, and kidneys for the tail vein-injected
mice, and heart, lungs, spleen, and kidneys for the portal
vein-injected mice, had almost no fluorescence (data not
shown).
Fig. 4C and D showed luciferase gene expression in the
various organs. In the case of the tail vein injection of the
PCL–DNA complexes, the luciferase gene was expressed
Fig. 5. In vivo transgene activity of PCL with various helper lipids. PCLs
composed of cetyl PEI and DPPC (5:100), cetyl PEI, DPPC, and cholesterol
(5:67:33 or 5:50:50), cetyl PEI and DOPE (5:100), cetyl PEI, DOPE, and
cholesterol (5:67:33) or cetyl PEI and cholesterol (5:100) were complexed
with pCAG-luc3 (30 Ag) at a 36 eq. N/P ratio. The PCL–DNA complexes
were injected in mice via a tail vein. At 24 h after injection, the expression
of luciferase in the lungs was quantified as described in Materials and
methods. Data represent the meanFS.D. (n=3). Chol, cholesterol. Asterisk
indicates a significant difference from the data for DPPC/Chol (1:0), DPPC/
Chol (1:1), and Chol. (P<0.01).
Fig. 6. Transgene activity obtained with PCLs, cetyl PEI, and PEI. Plasmid
pCAG-luc3 (30 Ag) was complexed with PEI, cetyl PEI, or PCLs composed
of cetyl PEI, DPPC, and cholesterol (5:67:33); and the complexes, as well
as plasmid alone, were injected into mice via a tail vein. At 24 h after
injection, the expression level of luciferase in lung was determined. Data
represent the meanFS.D. (n=3). Asterisk indicates a significant difference
from the other data (P<0.01).
Fig. 4. PCL-mediated gene transfer in vivo after injection of PCL–DNA
complexes into mice via a tail or the portal vein. Plasmid pEGFP-C1 (20 Ag)
was complexed with PCL composed of cetyl PEI, DPPC, and cholesterol
(5:67:33) at the optimal ratio (36 eq.) and was injected in 8-week-old ddY
male mice via a tail (A) or the portal (B) vein. At 24 h after injection, GFP
expression in the lungs (A) and liver (B) was observed under a fluorescence
microscope as described in Materials and Methods. Also, plasmid pCAG-
luc3 (20 Ag) was complexed with PCLs and the complexes were injected via
a tail (C) or the portal (D) vein. At 24 h after injection, the expression of
luciferase in heart (H), lung (Lu), liver (Li), spleen (S), and kidney (K) was
quantified as described in Materials and methods. N.D. indicates that the
luciferase expression was not detected. Scale bars, 100 Am. Data (C, D)
represent the meanFS.D. (n=3).
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the portal vein injection, luciferase gene was dominantly
expressed in the liver. Therefore, the target organs for gene
expression in vivo mediated by PCL were strongly depend-
ent on the injection route.
3.3. In vivo gene transfer mediated by PCLs with various
helper lipids
Next, we examined the gene transfer after tail vein
injection of mice with PCLs having various compositions
of helper lipids. Plasmid pCAG-luc3 (30 Ag per mouse) was
used as the reporter gene. PCLs comprising DPPC and
cholesterol (2:1 molar ratio) with cetyl PEI were the most
efficient for gene transfer (Fig. 5). Interestingly, PCLs
composed of DOPE and cetyl PEI, which were far more
efficient for gene transfer in vitro compared with those
comprising DPPC, cholesterol, and cetyl PEI, were less
efficient in vivo. When DPPC alone or cholesterol alone
was used as a helper lipid of PCLs, the amount of expressed
luciferase was only 2% and 6%, respectively, of that afterinjection with PCLs composed of DPPC, cholesterol (2:1),
and cetyl PEI.
3.4. In vivo gene transfer mediated by PCL, cetyl PEI, and
PEI alone
Since the helper lipids of PCL strongly affected the
efficiency of gene transfer, the liposomal formulation of
PCL is an important factor for gene transfer. To confirm this,
we examined the gene transfer by cetyl PEI or PEI alone
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posed of cetyl PEI, DPPC, and cholesterol (Fig. 6). Gene
expression after injection of PEI–DNA or cetyl PEI–DNA
complexes was less than one tenth of that after injection of
PCL–DNA complexes, indicating that liposomal formula-
tion is actually important for gene transfer, although PEI and
cetyl PEI themselves help to promote the transgene activity
to some extent. The figure also shows the gene expression
after injection of the pCAG-luc3 plasmid alone, which was
only less than 1% of that after injection of PCL–pCAG-luc3
complex.
3.5. Optimization of PCL-mediated gene transfer in vivo
Lastly, we examined the optimal conditions for gene
transfer by use of PCLs. PCL helper lipids were fixed to
DPPC and cholesterol (2:1), and PCL–pCAG-luc3 com-
plexes were injected in mice via a tail vein. Then, the
amount of luciferase expressed in the lungs was determined.
Fig. 7A shows the effect of modification amount of PEI
used to modify the liposomes. Liposomes modified with 5
mol% of cetyl PEI (DPPC/cholesterol/cetyl PEI=67:33:5)Fig. 7. Optimization of transgene activity of PCL. (A) PCLs were prepared with
complexed with 30 Ag of pCAG-luc3 at a 36 eq. N/P ratio, they were injected in m
assayed as described in Materials and methods. Data represent the meanFS.D. (n=
complexed with 30 Ag of pCAG-luc3 at various N/P ratios, and injected in mice via t
determined. (C) PCLs prepared with cetyl-PEI, DPPC, and cholesterol (5:67:33) we
and injected in mice via a tail vein. At 24 h after injection, luciferase gene expressio
N/P ratio were injected into mice via a tail vein. At the indicated times after injecwere the most efficient for gene transfer. Next, the optimum
ratio of PCL and DNAwas examined (Fig. 7B). The ratio of
PEI nitrogen and DNA phosphorus (N/P) was varied from
24 to 48 equivalents. As a result, 36 eq. of N/P ratio gave
the highest transgene expression. Concerning the amount of
plasmid, the more PCL plasmid was injected, the greater the
expression (Fig. 7C). Finally, from the time course data of
gene expression, the highest gene expression was observed
from 12 and 24 h after injection, indicating that the
luciferase gene expression was transient (Fig. 7D).4. Discussion
The PCL was developed as a safe and efficient gene
transfer system [23,24], possessing the advantages of cati-
onic liposomes and polycations, both of which are generally
used as nonviral gene transfer systems. We previously
observed that PCLs afforded high transgene efficiency with
low cytotoxicity in comparison with conventional cationic
liposomes [23]. Preliminary results also showed that PCL
could be applicable for in vivo use. In the present study, wevarious cetyl PEI/lipids (DPPC/cholesterol=2:1) ratios. After they had been
ice via a tail vein. At 24 h after injection, luciferase expression in lungs was
3). (B) PCLs prepared with cetyl-PEI, DPPC, and cholesterol (5:67:33) were
he tail vein route. At 24 h after injection, the gene expression in the lungs was
re complexed with the indicated amounts of pCAG-luc3 at a 36 eq. N/P ratio,
n was determined. (D) PCLs complexed with pCAG-luc3 (30 Ag) at a 36 eq.
tion, luciferase expression in the lungs was determined. N.D., not detected.
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for such usage.
At first, the expression efficiency of transgenes delivered
by PCLs in the presence of serum was examined. The
efficiency of PCLs composed of DOPE was highly
enhanced in the presence of serum, whereas that of PCLs
composed of DPPC and cholesterol was unaffected by the
serum. The reason for this difference is not clear at present.
However, gene transfer efficiency of other cationic lip-
osomes is often decreased or diminished in the presence
of serum, and the reason is thought to be the binding of
negatively charged serum proteins to the cationic liposomes,
which reduces the electrostatic interaction of the cationic
liposome with the target cell membrane [25,26]. Further-
more, serum protein binding may induce aggregation of
cationic liposomes, which may also reduce the uptake of
cationic liposome–DNA complexes into cells [27,28]. In
fact, the turbidity of certain cationic liposomes was
increased more than 10-fold in the presence of serum [29].
In our experiment the turbidity of PCL–DNA complexes,
however, was not much influenced by the presence of
serum, especially in the case of PCLs composed of DPPC
and cholesterol (Fig. 3). It is possible that this property
causes the PCL–DNA complexes to be resistant to serum.
Alternatively, it is reported that serum factors such as oleic
acid and heparin destroy the cationic liposome–DNA com-
plex [30]. If this is one of the reasons for the decrease in
transgene activity with delivery by cationic liposomes,
PCLs might be resistant to serum because of their more
stable structure.
DOPE is commonly used as a helper lipid in cationic
liposomal systems in vitro, since it is a typical nonbilayer
lipid and induces fusion or destabilization of the endosomal
membrane after the uptake of cationic liposome–DNA
complexes into a target cell [31]. However, for in vivo
systems, liposomal stability in the bloodstream is an impor-
tant factor. In fact, PCLs composed of DPPC, cholesterol,
and cetyl PEI showed more efficient gene transfer than those
containing DOPE as a helper lipid (Fig. 5), although the
latter was far efficient for gene transfer than the former in
vitro (Fig. 2). Similar evidence was also obtained for
cationic liposomes; i.e., the substitution of DOPE with
cholesterol as a helper lipid of cationic liposomes resulted
in more effective transgene expression in vivo [32,33].
Next, we determined the target organs that expressed
foreign genes after the administration of PCL–DNA com-
plexes via either the tail or portal vein route. In both cases,
the genes were expressed in the first organ encountered,
namely, the lungs after tail vein injection and the liver after
portal vein injection. Similar results were obtained after
administration of cationic liposome–DNA complexes, since
the aggregation of the complexes caused them to be physi-
cally trapped in the first organ reached [34,35]. PCLs
composed of DPPC, cholesterol, and cetyl PEI, however,
did not make aggregates in the presence of serum (Fig. 3).
Therefore, the reason for the gene expression in the organfirst encountered would be different in the PCL case. Since
PEI has high affinity for the negatively charged plasma
membrane, PCLs may interact strongly with the organ first
reached by the PCL–DNA complexes after administration.
The early distribution of a vector–DNA complex is impor-
tant for deciding the gene-expressing organ [36].
For the purpose of transgene delivery to organs besides
the first organ encountered, modification of a vector with
hydrophilic compounds such as polyethylene glycol (PEG)
was attempted [37,38]. In fact, PEG modification decreases
the binding of plasma proteins and increases the circulation
time of liposomes in the bloodstream, although the inter-
action of the cationic surface of the vector with the plasma
membrane of the target organ is weakened. Other attempts
have been made to deliver genes to specific organs by a
modification of a vector with specific ligands such as
carbohydrates [39], integrin ligands [40,41], and trasferin
[42].
Finally, we examined the optimal conditions for the use
of PCL in vivo. Since PCLs transferred the reporter gene
quite well compared with cetyl PEI or PEI alone, the
presence of helper lipids is quite important for the effective
gene transfer. Thus we determined the optimal amount of
helper lipids. As was shown in Fig. 7, the use of PCLs
composed of DPPC, cholesterol, and cetyl PEI (67:33:5
molar ratio) resulted in remarkable transgene activity,
whereas PCLs with twice as much cetyl PEI or one half
as much cetyl PEI were much less effective. The appropriate
covering of liposomal surface with PEI might be important,
although the precise topology of PEI on the liposomal
surface is unclear at present.
The optimal N/P ratio in vivo was as high as 36
equivalents. However, since half of the PEI may be present
at the inner surface of unilamellar liposomes and less than
half of PEI in the case of multilamellar vesicles, the actual
N/P ratio of PEI at the liposomal surface to the DNA might
be expected to be less than 36 equivalents. It was also
reported that the optimal charge ratio of cationic liposomes
to DNA shifted to the positive side when a cationic lip-
osomal system was used in vivo [43,44]. As was shown in
Fig. 7, PCL-mediated gene expression was transient. Since
the plasmid DNA is not inserted into host genomic DNA
when nonviral systems are used, transient gene expression is
also observed when cationic liposomal systems are used
[45].
PEI is a positively charged polymer and is used as a gene
transfer vector by itself [46,47], although the molecular
weight of PEI used for this purpose is usually quite high
(25,000 to 50,000), compared with the PEI used for PCLs
(1800 was used in this study). PEI has advantages compared
with other polycations: It is efficient for gene delivery
without using endosome-disrupting agents such as chloro-
quine and fusogenic peptides, since PEI has a number of
amines that can be protonated under low pH conditions, in
which case an influx of excess chloride ions into the
endosome occurs, which is followed by osmotic bursting
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cytosol is effectively transferred to the nucleus. In fact, it
was reported that PEI has the ability to enter the nucleus
[22] and to accelerate gene entry into the nucleus from the
cytosol [20]. On the other hand, the cationic liposome is
quite effective for the delivery of DNA into the cytosol
through the endosomal pathway but the entry of the cyto-
solic DNA into the nucleus is not satisfactory [15,16].
Therefore, the PCL, which has advantages of both cationic
liposomes for cytosolic delivery of DNA and polycations
for delivery of cytosolic DNA into the nucleus, would be a
quite effective nonviral vector for in vivo gene delivery.Acknowledgements
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